PET scan test for multiple myeloma response and treatment effect
Part of Cancer clinical trials.
This Phase 1 trial tests a special PET scan tracer called 18F-fludarabine to help doctors better assess multiple myeloma at the start of treatment and right after treatment ends. The goal is to see how well this imaging tool can show disease activity so care can be tailored more accurately.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have symptomatic multiple myeloma and are starting first-line treatment (the initial approach).
- You are not a candidate for autologous bone marrow transplant (your own cells).
- Your myeloma can be measured, either by a blood test for a monoclonal protein or by free light chain levels (in blood or urine).
- You are considered well enough for study procedures (Karnofsky 70+ or ECOG 0–1).
- If you could become pregnant, you must have a recent pregnancy test and use reliable birth control during the study and afterward.
- Your main blood and organ tests must be safe (including not having very low white cells/platelets, and kidney/liver function above set limits).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study uses a special imaging test called a PET scan to learn more about multiple myeloma and how it responds to treatment. The results may help doctors better predict outcomes and tailor care for people with newly diagnosed disease.
This Phase 1 study tests a new special scan marker (a radioactive imaging agent) to see whether it can detect certain multiple myeloma spots in the body. If it works, it may help doctors better locate disease using a PET-style scan.
This trial tests whether a special PET/CT scan (using fluciclovine, a radioactive tracer) can more clearly see multiple myeloma in the body. It may help doctors evaluate the extent of the disease and guide treatment decisions.
This trial compares two types of PET/CT scans to see which one better finds lesions (areas of disease) in people with newly diagnosed multiple myeloma. If you qualify, you may help doctors choose the most useful scan to guide care.
This trial compares a new type of PET/MR scan (using a radioactive tracer called Ga-68 PentixaFor) with standard imaging to see if it can better detect multiple myeloma at diagnosis and during follow-up. It may help improve staging and treatment planning.
This study tests a new imaging agent that may help doctors see multiple myeloma more clearly. It uses a special radioactive tracer that targets a protein found on myeloma cells, which could improve diagnosis and monitoring of the disease.
Hear when a new Myeloma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.